Invention Grant
- Patent Title: Compounds as diacylglycerol acyltransferase inhibitors
-
Application No.: US14943091Application Date: 2015-11-17
-
Publication No.: US09624174B2Publication Date: 2017-04-18
- Inventor: Mui Cheung , Raghuram S. Tangirala
- Applicant: GlaxoSmithKline LLC
- Applicant Address: US DE Wilmington, New Castle
- Assignee: GlaxoSmithKline LLC
- Current Assignee: GlaxoSmithKline LLC
- Current Assignee Address: US DE Wilmington, New Castle
- Agent Duke M. Fitch; Kathryn A. Lutomski; Edward R. Gimmi
- Priority: IN3480/DEL/2012 20121109
- Main IPC: A61K31/50
- IPC: A61K31/50 ; A61K31/501 ; A61K31/4965 ; A01N43/40 ; A61K31/44 ; A01N43/78 ; A61K31/425 ; C07D401/00 ; C07D403/00 ; C07D405/00 ; C07D409/00 ; C07D411/00 ; C07D413/00 ; C07D417/00 ; C07D419/00 ; C07D213/04 ; C07D277/00 ; C07D213/72 ; A61K31/122 ; C07D237/20 ; C07D213/74 ; C07D277/42 ; C07D401/12 ; C07D405/12 ; C07D417/12

Abstract:
Compounds of Formula (I) are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), useful in the treatment of obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.
Public/Granted literature
- US20160068487A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Public/Granted day:2016-03-10
Information query